VCARE STEM CELL THERAPY
Vcare has launched two treatments options based on stem cell products, one for diffused alopecia, the reversible form of hair loss and one for Androgenetic alopecia, commonly called as "Baldness".From:VCare TrichologyViews:1 0ratingsTime:04:36More inHowto Style

Read more here:
VCARE STEM CELL THERAPY - Video

Recommendation and review posted by simmons

Princess Margaret Cancer Program will implement ComprehensiveBMT and Investigate Cell Therapy to continue leading role in cancer care and research

SALT LAKE CITY , Nov. 14, 2012 /CNW/ - Remedy Informatics, the leading provider of registries and research informatics software for Life Science and Translational Research and Healthcare, today announced the Princess Margaret Cancer Centre at University Health Network in Toronto has selected ComprehensiveBMT and Investigate Cell Therapy, two of Remedy's innovative clinical informatics solutions.

(Logo: http://photos.prnewswire.com/prnh/20120206/SF47874LOGO)

"The Princess Margaret is one of the largest comprehensive cancer facilities in the world with the largest Blood and Marrow Transplant program in Canada and a gold standard cancer research facility," said Gary Kennedy , Founder and CEO of Remedy Informatics. "Both InvestigateCT and ComprehensiveBMT offer unmatched integration of information to improve treatment outcomes by aggregating, mapping, harmonizing and analyzing data across clinical and scientific disciplines. Valuable information will give valuable insights into patient safety, patient survivorship, and quality improvement for transplant physicians, nurses and researchers."

Built on Remedy's flagship Mosaic Platform, InvestigateCT and ComprehensiveBMT offer the Princess Margaret the world's first and only truly integrated research management system. In addition to combining blood and marrow registries with cell therapy laboratories and biobanks, clinicians and researchers will have an unprecedented view of their data through the Mosaic Ontology, which aggregates, maps and harmonizes the data to facilitate pattern recognition. Together researchers are able to manage and aggregate more data sources, across disciplines, including next-generation sequencing, cross-disease registries, LIMS and the Blood and Marrow Transplant Program to advance research of cell therapies, blood and marrow transplantation, and related diseases.

"The future of patient care and innovative research in blood and marrow transplantation requires rapid data analysis to track and improve patient outcomes. We are confident Remedy Informatics can meet our needs," said Dr. John Kuruvilla , MD, FRCP(C), director, Clinical Program, Blood and Marrow Transplant program at the Princess Margaret . "We foresee better information management as the cornerstone for improving patient outcomes in hematologic malignancies."

The Princess Margaret BMT program has an international reputation as a global leader in clinical and research programs and as a gold standard in transplant technologies like Apheresis collections for peripheral stem cell transplant infusions and Extracorporeal Photopheresis for selected graft-vs-host conditions. Over the next year, Remedy will work with the Princess Margaret BMT program to implement InvestigateCT, the world's first Integrated Research Management System designed for cancer centers involved in clinical research using cell therapies. InvestigateCT will facilitate multi-directional data flow throughout the BMT program, cell therapy labs and biobanks to improve real-time analytics, therapies, patient safety, and quality across the transplant care pathway as well as long-term patient survivorship for patients who are living longer and healthier lives.

Remedy serves a wide range of leading Life Science and Translational Research institutions across the country, including the Huntsman Cancer Institute at the University of Utah, Cleveland Clinic's Bariatric and Metabolic Institute and Heart and Vascular Institute, the American Joint Replacement Registry, Baylor Health Care System, and many more.

For more information about Investigate Cell Therapy or ComprehensiveBMT, or Remedy's leading patient registry technology, please visit our website, http://www.remedyinformatics.com. InvestigateCT is for research use only and is not intended for clinical or cell processing purposes.

About Remedy Informatics, Inc.

Link:
The Princess Margaret BMT Program Chooses Remedy Informatics' Blood and Marrow Transplant & Cell Therapy Solutions to ...

Recommendation and review posted by simmons

jodyMSvideo2012 0001
Center for Biologics Evaluation and Research Consumer Affairs Branch Food and Drug Administration 1401 Rockville Pike, Suite 200N/HFM-47 Rockville, MD 20852-1448 We are writing to encourage the FDA and the Center for Biologics Evaluation and Research (CBER) to approve a clinical trial of mesenchymal stem cell derived neural progenitors (MSC-NPs) in the treatment of Secondary Progressive Multiple Sclerosis (SPMS). The initial 20 person trial will be conducted at the Multiple Sclerosis Research Center of New York (MSRCNY) under the direction of Dr. Saud Sadiq, neurologist and director of the MSRCNY. Dr. Sadiq was previously the head of Neurology at St. Luke #39;s Roosevelt Hospital in New York City (NYC). In 2006, he started this research center in NYC working only on MS. In November 2011, the MSRCNY received approval from the Institutional Review Board (IRB) of the International Cellular Medicine Society (ICMS) to conduct this trial for patients with SPMS, the first of its kind ever done in the US. This trial is very specialized as it uses a patient #39;s own adult stem cells that are removed from the patient #39;s breast bone marrow, grown, isolated and injected into the spinal fluid (intrathecal) where the disease attacks the myelin. The trial will last for 3 years with stem cell treatments every 3 months for the first year and potentially more, depending on the many evaluations to determine physical and mental progress. MSRCNY requested approval in the past and is currently seeking ...From:Jennifer DavidViews:2 0ratingsTime:08:46More inNonprofits Activism

See the article here:
jodyMSvideo2012 0001 - Video

Recommendation and review posted by simmons

Best of Times, Worst of Times - Michael Conte, MD
Dr. Conte describes the current state of vascular surgery, treatment and research and how the Vascular Cures Research Network advances Personalized Medicine.From:VascularResearchViews:7 0ratingsTime:03:05More inNonprofits Activism

Go here to read the rest:
Best of Times, Worst of Times - Michael Conte, MD - Video

Recommendation and review posted by sam

Personalized Medicine - Bill Asher, Brenda Jarrell and Gerald Quirk
Choate partners Bill Asher, Brenda Jarrell and Gerald Quirk discuss personalized medicine.From:choateTVViews:3 0ratingsTime:05:23More inPeople Blogs

Go here to read the rest:
Personalized Medicine - Bill Asher, Brenda Jarrell and Gerald Quirk - Video

Recommendation and review posted by sam

Surgeon-Scientist
This short video gives us a glimpse into the world of Michael Conte, MD and how the Vascular Cures Research Network advances Personalized Medicine. What inspires him, what makes him want to get up everyday and go to work and what are the things that keep him and his colleagues looking for a cure?From:VascularResearchViews:3 0ratingsTime:03:35More inNonprofits Activism

Original post:
Surgeon-Scientist - Video

Recommendation and review posted by sam

Michael Snyder, "Personalized Medicine: How I Used Genomics to Discover, Track and Stop My Diabetes"
The cost of genome sequencing has dropped dramatically in recent years. Do you want to get your genome seqeunced? We will explore how genome sequencing can be used in medicine and health care and its implications. Michael Snyder is the Stanford Ascherman Professor and Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine. This Classes Without Quizzes lecture was filmed on location at Stanford Reunion Homecoming 2012 by the Stanford Alumni Association.From:StanfordAlumniViews:4 0ratingsTime:01:08:31More inEducation

Excerpt from:
Michael Snyder, "Personalized Medicine: How I Used Genomics to Discover, Track and Stop My Diabetes" - Video

Recommendation and review posted by sam

Play therapy for 17 month old boy with spinal cord injury
We are always aware of trying to move Evander as he would if he was able to crawl or walk. Repetition of normal movements such as - crawling, climbing, sliding is an important part of his day-to-day rehabilitation.From:EvanderConroyViews:9 0ratingsTime:01:08More inPeople Blogs

More:
Play therapy for 17 month old boy with spinal cord injury - Video

Recommendation and review posted by sam

SarahPerez
Sarah Perez 11 years old C6-T4 Spinal Cord Injury Project Walk AtlantaFrom:AtlantaProjectWalkViews:0 0ratingsTime:03:07More inNonprofits Activism

Original post:
SarahPerez - Video

Recommendation and review posted by sam

Ashley and James- Spinal Cord Injury Awareness Week
From:BrooksHealthViews:2 0ratingsTime:01:21More inSports

Read the original here:
Ashley and James- Spinal Cord Injury Awareness Week - Video

Recommendation and review posted by sam

Aruna Hari Sharma on Phillips C10 TEM in University of Miami Dietrich #39;s Lab Nov 13, 2012.mov
Aruna Hari Sharma from Uppsala University were invited to work on Transmission Electron Microscopy on Grids pertaining to the brain and spinal cord injury under various protocols in University of Miami, FL, USA. Dalton Dietrich, Director of the Institute Miami Project to Cure Paralysis and Helen Bramlett have great interest in CNS injury and neuroregeneration. Since they are good friends of Aruna Hari Sharma since 80 #39;s they are now working together on various aspects of CNS injury. In this video Aruna is seen doing TEM on grids from injured brains. Hari is also seen in helping Aruna to achieve the target.From:Hari SharmaViews:0 0ratingsTime:02:15More inScience Technology

Continue reading here:
Aruna

Recommendation and review posted by sam

Spasms 3 1/2 yrs
Spinal cord injury leg spasms from touch 3 1/2 yrs postFrom:britbrit317Views:8 0ratingsTime:01:02More inPeople Blogs

Read the original here:
Spasms 3 1/2 yrs - Video

Recommendation and review posted by sam

Pulkit Gupta Taking first steps after spinal cord injury. Sharing the Happy Moments by Prodyut Das
Pulkit Gupta suffered road traffic accident due to which he got complete spinal cord injury #D4-5, # tibia bone head injury. After taking intense training and exercises, this is his first walk. http://www.physiotherapy-treatment.comFrom:Prodyut DasViews:0 0ratingsTime:00:31More inEducation

Continue reading here:
Pulkit Gupta Taking first steps after spinal cord injury. Sharing the Happy Moments by Prodyut Das - Video

Recommendation and review posted by sam

Egan Wellness Anti Aging Skin Care Spa Video | Spa in Covington
my.datasphere.com Egan Wellness Skin Care Spa! The best in primary care, preventative medicine and aesthetic services! Pamela Egan, Nurse Practitioner has completed a Fellowship with the American Academy of Anti-Aging Regenerative Medicine. We are focused on providing high-quality service and customer satisfaction - we will do everything we can to meet your expectations. Our company is based on the belief that our customers #39; needs are of the utmost importance. Our entire team is committed to meeting those needs. As a result, a high percentage of our business is from repeat clients and referrals. Look Good Feel good with Evidenced-based conventional and natural methods including "Natural Hormone Replacement, Metabolic, and Nutritional Medicine" for men women. We also offer a full complement of skin treatments including Venus Freeze, designer facials, chemical peels, Botox Fillers. Whether you #39;re looking to obtain optimum health or to pamper yourself, the professionals at Egan Wellness Skin Care Spa are eager to meet all of your needs. Give us a call at (985) 892-3031 to schedule your appointment or visit us at http://www.pamelaegan.com to learn more about the services we offer. 12545376 Facials, Microdermabrasion, LED Light Therapy, Lipolysis, Collagen and Elastic Restructuring, Syneron Auroro IPL, Prestige Peel (Mid Depth), Brilliance Peel, Venus Freeze, Covington, WWLFrom:DataSphereVideosViews:1 1ratingsTime:01:17More inPeople Blogs

Read the original:
Egan Wellness Anti Aging

Recommendation and review posted by sam

Making It Cool: Gen Z Meets Manufacturing
Aspiring roboticists are seeking to change the way we live, work, play and fight wars through artificial intelligence; 3D printing has taken college classrooms by storm allowing art students to create mold models once reserved for technical professionals, and students in institutes of regenerative medicine are actually manufacturing organs for humans and animals. So what makes manufacturing cool? How do we get today #39;s youth excited about new opportunities in manufacturing? Listen to our live broadcast as our panelists talk about making manufacturing cool. Panelists: Chris Anderson, Editor of Wired Magazine and CEO of 3D Robotics Adam Friedman, Director of the Pratt Center for Community Development Aly Khalifa, President at Gamil Design, Inc. Joe LaRussa, Director of Membership at Society of Manufacturing Engineers AJ Sweatt, Principal at AJ Sweatt Logic CommunicationsFrom:Anita Brown-GrahamViews:0 0ratingsTime:59:34More inNews Politics

See more here:
Making It Cool: Gen Z Meets Manufacturing - Video

Recommendation and review posted by sam

Tissue Engineering And Regenerative Medicine: Advancing Toward Clinical Therapies : Chapter 1 From T
ll4.me Tissue Engineering And Regenerative Medicine: Advancing Toward Clinical Therapies : Chapter 1 From Transitional Approaches In Tissue Engineering Reg Chapter 1 from Translational Approaches in Tissue Engineering and Regenerative Medicine,Jeremy J. Mao, Gordana Vunjak-Novakovic, Antonios G. Mikos, Anthony Atala, Editors Publisher: Artech House Publishers Illustration: N Language: ENG Title: Tissue Engineering and Regenerative Medicine: Advancing Toward Clinical Therapies : Chapter 1 from Transitional Approaches in Tissue Engineering Reg Pages: 00000 (Encrypted PDF) On Sale: 2007-11-30 SKU-13/ISBN: 9781607832362 Category: Technology Engineering : General Chapter 1 from Translational Approaches in Tissue Engineering and Regenerative Medicine,Jeremy J. Mao, Gordana Vunjak-Novakovic, Antonios G. Mikos, Anthony Atala, Editors Publisher: Artech House Publ technology, engineering, generalFrom:shirleymiller364Views:0 0ratingsTime:00:14More inPeople Blogs

Read the original post:
Tissue Engineering And Regenerative Medicine: Advancing Toward Clinical Therapies : Chapter 1 From T - Video

Recommendation and review posted by sam

Jill Helms, "Forever Young: The New Frontier of Stem Cell Medicine"
The good part about getting older is that we gain some wisdom and patience. The bad part is that our bodies start to wear out. But what if we could revitalize our damaged bits back to a healthy state? Come hear what the field of Regenerative Medicine is striving to achieve, and learn how it all begins with the stem cell. Jill Helms is a professor in Plastic and Reconstructive Surgery in the department of surgery at Stanford University #39;s School of Medicine. This Classes Without Quizzes lecture was filmed on location at Stanford Reunion Homecoming 2012 by the Stanford Alumni Association.From:StanfordAlumniViews:11 0ratingsTime:54:05More inEducation

Excerpt from:
Jill Helms, "Forever Young: The New Frontier of Stem Cell Medicine" - Video

Recommendation and review posted by sam

ANAHEIM, Calif., Nov. 13, 2012 /PRNewswire/ --A step ahead of the colossal skincare market, Ageless Derma, an innovative, anti-aging skincare company, leads its competition as the first to integrate the latest technology, PhytoCellTec. This cutting-edge technology cultivates stem cells from a rare apple and when incorporated into the Ageless Derma Stem Cell and Peptide Anti-Wrinkle cream, has proven to diminish wrinkles with exceptional results.

Patent pending, PhytoCellTec Malus Domestica is a liposomal preparation of apple stem cells designed to protect skin stem cells. Known for minimal shriveling and extended longevity, the Uttwiler Spalauber apple is rich in proteins, phytonutrients, and long-living cells. PhytoCellTec Malus Domestica is a scientifically proven breakthrough that effectively combats skin aging.

"We were excited to find new, revolutionary stem cell technology," said Dr. Farid Mostamand, owner and founder of the Ageless Derma skincare line. "This extraordinary process is a leap forward. Our customers want non-surgical options to fight wrinkles and sagging skin and PhytoCellTec technology provides exactly that. This has produced remarkable results for eliminating wrinkles so we integrated it into our Ageless Derma anti-wrinkle cream."

Pioneered by Mibelle BioChemistry Group, the founding company hosts scientific studies to substantiate claims that PhytoCellTec Malus Domestica provides revolutionary skin rejuvenation. Honored with the BSB Innovation Award in 2008 for best ingredient, Mibelle BioChemistry Group developed PhytoCellTec technology to enable plant stem cells to grow in considerable numbers. In comprehensive studies the company was able to prove PhytoCellTecMalus Domestica, the dynamic ingredient derived from the apple stem cells, supports longevity and vitality of skin stem cells.

In a study of volunteers ranging in age from 37 to 64, 100% of the subjects showed significant decreases in wrinkle depth. The volunteers applied a concentration of 2% PhytoCellTec Malus Domestica twice daily for 28 days to "crow's feet," or wrinkles near the eyes, to diminish wrinkles.

PhytoCellTec enables the cultivation of stem cells by using the same repair methods plant cells use. The PhytoCellTec process selects a diminutive piece of plant material which is then damaged to result in callus formation. The formations are incubated and harvested in order to obtain stem cells.

"Along with this miraculous stem cell factor, our anti-aging creams have other effective, safe ingredients such as vitamins, minerals, and peptides. Peptides also play a big role in our anti-wrinkle creams as they stimulate collagen growth to keep skin looking young," said Dr. Mostamand.

About Ageless Derma:

Ageless Derma is accredited with the Better Business Bureau and offers a 30-day money-back guarantee. Ageless Derma products are available at Focus Medical Spa in Anaheim, CA, through the website http://www.agelessderma.com, or toll-free (877) 777-1940. For more information on Ageless Derma, please contact Dr. Farid Mostamand at mostamand5@gmail.com or call (877) 777-1940.

Contact

Continued here:
Ageless Derma Formulates Apple Stem Cells into Anti-Wrinkle Cream with PhytoCellTec Technology

Recommendation and review posted by Bethany Smith

What Are Stem Cells | Stem Cell Malaysia
stemcellmalaysia.com Stem cells are non-differentiated cells with the ability to divide and produce any body cell types. The ability of stem cells to differentiate and self-regenerate impart great possibilities for disease treatment other than for restoring health, beauty and anti-aging. Clinically proven for certain illness and conditions, stem cells can now be introduced into the body to repair and replace damaged organ or tissue. For more informative articles on stem cells and stem cell therapy, please visit Stem Cell Malaysia at http:/stemcellmalaysia.com/.From:stemcells2012Views:2 1ratingsTime:06:29More inHowto Style

See more here:
What Are Stem Cells | Stem Cell Malaysia - Video

Recommendation and review posted by Bethany Smith

My Hair Care Routine Favorite Products
Below are all the items mentioned in the video: Ovation Cell Therapy System (they have the holiday set an use the code survey2012) Organix coconut milk Loreal evercream TRESemme Thermal heat tamer Macadamia Healing Oil TRESemme 4+4 Styling glaze Paul Mitchel firm style dry wax Sexy hair play dirty textureizing hairspray/wax Hair Doughnut from Clairs or Sallys Wide tooth comb Teasing comb/brush (sallys) Revlon Hot air hair styler Like Subscribe 🙂 Don #39;t forget to follow me on Instagram Twitter @The1nonlymaria and now I have my blog.From:The1nonlymariaViews:1 1ratingsTime:19:29More inHowto Style

Read this article:
My Hair Care Routine

Recommendation and review posted by Bethany Smith

LITCHFIELDWith a name inspired by a Celtic goddess who could manifest magic for the good of others, an Elkhound mix that suffered the depths of animal abusenearly to the point of deathis benefiting from cutting-edge veterinary medicine at a practice in Bantam.

Rhiannon, whose name derives from the Stevie Nicks song about the legendary goddess, is one of two patients helping to make veterinary history in Connecticut through the states first in-clinic stem cell regenerative therapy treatments.

Such loving care stands in stark contrast to the condition Rhiannons owner, Edward Milne of Cheshire, found the 14-year-old in the first time he saw her.

I found her hanging by her neck from a tree as I was driving along a back country road in Northford, CT when she was about two years old, Mr. Milne wrote in an e-mail to the Bantam clinic, Animal Health Practice Inc.

When I confronted the owner, Mr. Milne wrote, he admitted that he had not fed her or provided her with water for some time, and when she didnt die, he hung her from the tree to finish her off. I guess it was fate that brought us together.

Another type of Rhiannon-esque fate brought the dog to a vet who is performing a ground-breaking procedure to treat severe arthritis in her elbow and back.

Rhiannon is the first dog to receive MediVet Americas non-controversial adipose regenerative stem cell therapy, according to a release sent by the company. MediVet is a global leader in veterinary science located in 29 countries. The company develops advanced cellular treatments and natural herbal remedies designed to maximize animal performance, repair, recovery and general wellness.

Were very excited to be the first veterinarians in Connecticut to offer this new technology, said Dr. Angela Erickson-Greco Monday morning.

In addition to Rhiannon, Dr. Erickson-Greco is also administering the treatment to Dakota, a Bernese Mountain Dog and Great White Pyrenees mix, who has bilateral ACL tears, which means she has torn a crucial ligament in both of her knees.

New Milford resident Cathy Morsey said Dakota had a limp in her front leg in the shoulder area at 6 months old. In January of last year, we had a wet snow and she slid on the snow and tore a cartilage in her knee, said Ms. Morsey. Continued...

Follow this link:
Rhiannon, an Abused Dog, and Dakota, Get Stem Cell Therapy in Litchfield

Recommendation and review posted by Bethany Smith

NEW YORK, Nov. 13, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NBS) ("NeoStem" or the "Company"), an emerging market leader in the fast growing cell therapy industry, today announced that the Company has completed the divestiture of its 51% ownership interest in Suzhou Erye Pharmaceutical Co. Ltd. ("Erye"), a China-based generic pharmaceutical company. The divestiture provides NeoStem with $12,280,000 in cash and removes from the Company's balance sheet over $30 million in short and long-term debt obligations. Erye also returns 1,040,000 shares representing approximately 0.7% of the Company's outstanding common stock, 1,170,000 stock options representing approximately 5.1% of the Company's outstanding options and 640,000 warrants to purchase common stock held by Erye representing approximately 1.1% of the Company's outstanding warrants.

"We are very pleased to have reached this significant milestone in our business," said Dr. Robin Smith, Chairman and CEO of NeoStem. "The Erye divestiture brings non-dilutive capital that bolsters our cash position in the United States, reduces legal and financial reporting expenditures, simplifies our financial statements and focuses our efforts exclusively on the rapidly growing cell therapy industry. The divestiture also paves the way for the Company to qualify for new funding through the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program which would support our pre-clinical development of VSELTM Technology. NeoStem will also be able to invest more resources into its cell therapy development and contract manufacturing activities."

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy industry. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic product candidate, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSEL TM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

For more information on NeoStem, please visit http://www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its contract development and manufacturing ("CDMO") business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

Excerpt from:
NeoStem Closes Divestiture of Its Ownership Interest in Suzhou Erye

Recommendation and review posted by Bethany Smith

THE WOODLANDS, Texas--(BUSINESS WIRE)--

Opexa Therapeutics, Inc. (OPXA), a company developing Tcelna, a novel T-cell therapy for multiple sclerosis (MS), today announced that Health Canada has approved the Company's Clinical Trial Application (CTA). The application was filed with the Biologics and Genetic Therapies Directorate. With this approval by the Canadian Health Authority, Opexa expects to expand its ongoing clinical trial in Secondary Progressive MS (SPMS) patients to include several sites in Canada. The Abili-T trial, a Phase 2b study of Tcelna in subjects with SPMS, is currently enrolling patients in the United States.

To date, over a half of the clinical sites have been initiated and approximately ten percent of subjects have been enrolled. Enthusiasm and support remains strong among the patients and the treatment sites. The trial is expected to enroll 180 patients in approximately 30 sites in the U.S. and Canada and conclude in 2015.

In addition, at the end of September, The United States Adopted Names Council (USANC) officially adopted Tcelnas non-proprietary name, imilecleucel-T. USANC is tri-sponsored by the American Medical Association, the United States Pharmacopeial Convention, and the American Pharmacists Association. USANC aims to standardize drug nomenclature by selecting informative and unique non-proprietary names for all pharmaceuticals marketed in the U.S. The name imilecleucel-T is derived from a set of regulations and guidelines set forth by USANC specific to cellular therapies. The non-proprietary name will be used in conjunction with the brand name, Tcelna, in publications and certain communication material appearing as Tcelna (imilecleucel-T).

We are very pleased with the progress of the Abili-T SPMS clinical trial to date, stated Neil K. Warma, President and CEO of Opexa. The clinical trial sites are being activated as planned and screening of patients for enrollment into the trial is on schedule due to the patients enthusiasm to participate in the trial and the efficient cooperation among the sites, our clinical staff and the various vendors. SPMS represents a market in dire need of new, safe and effective therapies. Currently there is only one FDA-approved treatment in the U.S. and it carries a safety warning that significantly limits its use. With the approval of the regulatory package by the Canadian Health Authority, we have taken another key step in the progress of the Abili-T trial, as it enables us to access large clinical practices that should enhance patient enrollment. Additionally, USANCs acceptance of Tcelnas non-proprietary name supports our rebranding effort and enables us to have more flexibility in meeting submission criteria in certain publications. We are also continuing to focus on securing the necessary capital required to continue and complete the trial, added Mr. Warma.

About SPMS

SPMS is a progressive phase of MS which is characterized by a steady progression of clinical neurological damage with or without relapses. After ten years of disease characterized by relapse events and remitting disability (RRMS), approximately 50 percent of patients will have progressed to SPMS. In SPMS, relapses dissipate over time and subjects experience general progression and increasing disability. It is believed that the resulting neurological damage cannot be reversed.

About Tcelna

Tcelna (imilecleucel-T) is a personalized therapy that is specifically tailored to each patient's disease profile. Tcelna is manufactured using ImmPath, Opexa's proprietary method for the production of a patient-specific T-cell immunotherapy, which encompasses the collection of blood from the MS patient, isolation of peripheral blood mononuclear cells, generation of an autologous pool of myelin-reactive T-cells (MRTCs) raised against selected peptides from myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP), and the return of these expanded, irradiated T-cells back to the patient. These attenuated T-cells are reintroduced into the patient via subcutaneous injection to trigger a therapeutic immune system response. Opexa believes the potential combination of efficacy, superior safety, excellent tolerability and administration may position Tcelna as an MS treatment of choice as compared to existing therapeutics.

About Opexa

See the rest here:
Opexa Receives Clinical Trial Approval From Health Canada for Novel T-Cell Therapy

Recommendation and review posted by Bethany Smith

SAN DIEGO--(BUSINESS WIRE)--

Cytori Therapeutics (CYTX) announced this morning that a peer-reviewed case series using Cytoris cell therapy to treat patients suffering from complex cryptoglandular fistula has been published in the current issue of the British Medical Journal: Case Reports. The patients were treated by Dr. David Borowski and Dr. Pud Bhaskar, Consultant Surgeons at the University Hospital of North Tees, a National Health Service (NHS) hospital in the United Kingdom.

In this case series, three patients suffering from long-standing complex cryptoglandular fistula-in-ano were treated using fat grafts enriched with their own adipose-derived stem and regenerative cells (ADRCs), processed using Cytoris Celution system. The ADRC-enriched graft was injected directly into the tissue surrounding the fistula to close the fistula track. The interior opening of the fistula was closed with a mucosal advancement flap. All three patients remain fully healed at two to three year follow-up, with one patient undergoing colostomy reversal to restore bowel continuity.

These three patients are the initial cases treated within a phase I feasibility study; all three had been suffering from the symptoms of their fistulae with considerable reduction in their ability to lead a normal life, said Dr. Borowski. Other treatments had failed, and the successful treatment with ADRC-enriched lipofilling has helped them to resume a normal lifestyle. With these encouraging results, we are currently collaborating with several other centers in the UK and Europe to explore the efficacy of this treatment in a greater number of patients, and for other indications, in the setting of clinical trials.

This successful case series at a respected NHS hospital in the UK illustrates the breadth of Cytoris soft tissue business and the potential of Cytoris cell therapy to help patients who have few, if any, alternative treatment options. The data, showing that ADRC-enriched fat grafting appears to be safe and feasible for cryptoglandular fistula patients, validates the expansion of Cytoris CE Mark claims to include cryptoglandular fistula and other soft tissue and wound indications in August of this year.

Based on a report of the American College of Surgeons, there are between 43,000 and 140,000 fistula cases per year in Europe, of which cryptoglandular fistula are a subset. Cryptoglandular fistula is the most common cause of persistent perianal infection, causing abnormal fecal contamination and potentially incontinence.

About Cytori

Cytori Therapeutics, Inc. is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple ischemic conditions. These therapies are made available to the physician and patient at the point-of-care by Cytoris proprietary technologies and products, including the Celution system product family. http://www.cytori.com

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those regarding the potential of Cytoris cell therapy to help no-option patients, and statements regarding the safety and feasibility of this procedure for cryptoglandular fistula patients, are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include the uncertainties regarding the collection and results of clinical data, as well as our history of operating losses, regulatory uncertainties, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" section in Cytori's Securities and Exchange Commission Filings on Form 10-K and Form 10-Q. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this press release.

Read this article:
Cryptoglandular Fistula Repair Case Series Using Cytori Cell Therapy Published in the British Medical Journal: Case ...

Recommendation and review posted by Bethany Smith

JERUSALEM--(BUSINESS WIRE)--

Gamida Cell Ltd., a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine, announced today that the first patient, enrolled in its pilot study of NiCord as an investigational treatment for sickle cell disease (SCD), has been transplanted at Duke University in North Carolina.

Gamida Cell CEO Dr. Yael Margolin said, The NiCord study is a first step in broadening Gamida Cells pipeline of cell therapies to treat patients who suffer from severe non-malignant diseases with a very large unmet clinical need.

SCD is a group of inherited red blood cell disorders where red blood cells become hard and sticky and look like a C-shaped farm tool called a sickle. According to statistics, SCD affects 90,000 to 100,000 in the US alone, mainly African-Americans and Hispanic-Americans. Symptoms range in type and severity. SCD can be fatal and to date, the only cure for SCD is stem cell transplantation from a family related matched donor.

Dr. Margolin continued, Sickle cell disease can be cured with a successful bone marrow transplantation, especially from a family related fully matched donor. Most patients do not pursue this option, since they do not have the suitable donor. NiCord is intended to reverse this situation and provide a readily available cure.

NiCord is an expanded cell graft derived from an entire unit of umbilical cord blood and enriched with stem cells. NiCord was developed based on Gamida Cells proprietary NAM technology.

The official name of the study is Allogeneic Stem Cell Transplantation of NiCord, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Combination With a Second, Unmanipulated Cord Blood Unit in Patients With Sickle Cell Disease. http://www.clinicaltrials.gov/ct2/show/NCT01590628?term=nicord&rank=1. A total of 10 patients, ages 2 21, will be enrolled in the NiCord study, a single center, single arm trial evaluating the safety and efficacy of transplanting NiCord together with a second un-manipulated cord blood unit in patients with SCD following myeloablative therapy. The study will also assess transplant-related mortality, event-free survival and overall survival at 100, 180 and 365 days, respectively.

About Gamida Cell

Gamida Cell is a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine. The companys pipeline of stem cell therapy products are in development to treat a wide range of conditions including blood cancers, solid tumors, non-malignant hematological diseases such as hemoglobinopathies, neutropenia and acute radiation syndrome, autoimmune diseases and metabolic diseases as well as conditions that can be helped by regenerative medicine. Gamida Cells therapeutic candidates contain populations of adult stem cells, selected from non-controversial sources such as umbilical cord blood, bone marrow and peripheral blood, which are expanded in culture. Gamida Cells current shareholders include: Elbit Imaging (EMITF), Clal Biotechnology Industries (CBI.TA), Israel Healthcare Venture, Teva Pharmaceutical Industries (TEVA), Amgen, Denali Ventures and Auriga Ventures. For more information, please visit: http://www.gamida-cell.com.

Continue reading here:
First Pediatric Sickle Cell Disease Patient Receives NiCord® Stem Cell Transplantation in Gamida Cell Pilot Study at ...

Recommendation and review posted by Bethany Smith